References
- Gold DT, Pantos BS, Masica DN, et al. Initial experience with teriparatide in the United States. Curr Med Res Opin 2006;22:703–8
- Tashjian AH, Jr, Gagel RF. Teriparatide [human PTH(1–34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 2006;21: 354–65
- Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone(1–34) for 2 years and relevance to human safety. Toxicol Pathol 2002;30:312–21
- Vahle JL, Long GG, Sandusky G, et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1–34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004;32:426–38
- Tashjian AH, Jr, Chabner BA. Commentary on clinical safety of recombinant human parathyroid hormone 1–34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res 2002;17: 1151–61
- Surveillance Research Program, National Cancer Institute SEER*Stat software (www.seer.cancer.gov/seerstat) version 6.1.4